Cancer issues

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 1, 2009, Pages 87-107

  Marsden, Jo ^a   Sturdee, David ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b SOLIHULL HOSPITAL   (United Kingdom)

Author keywords

breast cancer; endometrial cancer; hormones and cancer; HRT

Indexed keywords

CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; RALOXIFENE; SEX HORMONE; TAMOXIFEN; TIBOLONE;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESOPHAGUS CARCINOMA; GALLBLADDER CANCER; GALLBLADDER CARCINOMA; GALLBLADDER DISEASE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; MELANOMA; MONOTHERAPY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STOMACH CANCER; STOMACH CARCINOMA; TREATMENT DURATION; UTERINE CERVIX CANCER; VAGINA BLEEDING;

AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOMEN'S HEALTH;

EID: 58249092001     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2008.10.005     Document Type: Review

References (109)

1. Available from:. http://info.cancerresearchuk.org
2. Patel R.R., Sharma C.G., and Jordan V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 14 (2007) 113-122
3. Collins J.A., Blake J.M., and Crosignani P.G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11 (2005) 545-560
4. Collaborative Group on Hormonal Factors for Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies. Lancet 350 (1997) 1047-1060
5. Rossouw J.E., Anderson G.L., Prentice R.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
6. Chlebowski R.T., Hendrix S.L., Lander R.D., et al. for the Women's Health Initiative Randomised Trial. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289 (2003) 3243-3253
7. Anderson G.L., Chlebowski R.T., Rossouw J.E., et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55 (2006) 103-115
8. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
9. Stefanick M.L., Anderson G.L., Margolis K.L., et al., WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
10. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
11. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
12. Raudaskoski T., Tapanainen J., Tomás E., et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 109 (2002) 136-144
13. Peled Y., Perri T., Pardo Y., et al. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms - a review. Menopause 14 (2007) 550-554
14. Backman T., Rauramo I., Jaakkola K., et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106 (2005) 813-817
15. Trinh X.B., Tjalma W.A., Makar A.P., et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril (11 August 2007) [Epub ahead of print]
16. Elmore J.G., and Gigerenzer G. Benign breast disease - the risks of communicating risk. N Engl J Med 353 (2005) 297-299
17. Santen R.J., and Mansel R. Benign breast disorders. N Engl J Med 353 (2005) 275-285
18. Rohan T.E., Negassa A., Chlebowski R.T., et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 100 (2008) 563-571
19. Dupont W.D., Page D.L., Parl F.F., et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85 (1999) 1277-1283
20. Byrne C., Connolly J.L., Colditz G.A., et al. Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer 89 (2000) 2046-2052
21. Available from:. www.NICE.org.uk
22. Domchek S.M., and Rebbeck T.R. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 19 (2007) 27-30
23. Marsden J., Whitehead M.I., A'Hern R., et al. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible?. Fertil Steril 73 (2000) 292-299
24. Holmberg L., Anderson H., and for the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 363 (2004) 453-455
25. von Schoultz E., and Rutqvist L.E. on behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 97 (2005) 533-555
26. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 (2008) 475-482
27. Martin L.J., and Boyd N.F. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 10 (2008) 201
28. Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8 (2001) 29-34
29. Greendale G.A., Reboussin B.A., Sie A., et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130 (1999) 262-269
30. McTiernan A., Martin C.F., Peck J.D., et al. Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 97 (2005) 1366-1376
31. Chlebowski R.T., Anderson G., Pettinger M., et al. Women's Health Initiative Investigators. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 168 (2008) 370-377
32. Yasmeen S., Romano P.S., Pettinger M., et al. Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst 95 (2003) 429-436
33. Ganott M.A., Sumkin J.H., King J.L., et al. Screening mammography: do women prefer a higher recall rate given the possibility of earlier detection of cancer?. Radiology 238 (2006) 793-800
34. Fletcher A.S., Erbas B., Kavanagh A.M., et al. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. Breast 14 (2005) 192-200
35. Anderson W.F., Chatterjee N., Erhler W.B., et al. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76 (2002) 27-36
36. Biglia N., Mariani L., Sgro L., et al. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 14 (2007) 549-567
37. Marsden J., and A'Hern R. Progestogens and breast cancer risk: the role of hormonal contraceptives and hormone replacement therapy. J Fam Plann Reprod Health Care 4 (2003) 185-187
38. Wells M. The endometrium and hormone replacement therapy: risk of estrogen and endometrial cancer. In: O'Brien, and MacLean A.B. (Eds). Hormones and cancer (1999), RCOG Press, London 153-163
39. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 275 (1996) 370-375
40. Lethaby A., Suckling J., Barlow D.H., et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 3 (2004) CD000402
41. Pickar J.H., Yeh I.T., Wheeler J.E., et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: 2-year substudy results. Fertil Steril 80 (2003) 1234-1240
42. Weiderpass E. Risk of endometrial cancer following estrogen replacement with and without progestins. J Nat Cancer Inst 91 (1999) 1131-1137
43. Kelsey J.L., Livolsi V.A., Holford T.R., et al. A case-control study of cancer of the endometrium. Am J Epidemiol 116 (1982) 333-342
44. Antunes C.M.F., Stolley P.D., Rosenstein M.B., et al. Endometrial cancer and estrogen use. Report of a large case control study. N Engl J Med 300 (1979) 9-13
45. Paganini-Hill A., Ross R.K., and Henderson B.E. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 59 (1989) 445-447
46. Bergeron C., Nogales F., Masseroli M., et al. A multi-centric European study testing the reproducibility of the WHO classification of endometrial hyperplasias with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 23 (1999) 1102-1108
47. Edris F., Vilos G.A., Al-Mubarak A., et al. Resectoscopic surgery may be an alternative to hysterectomy in high risk women with atypical endometrial hyperplasia. J Minim Invasive Gynecol 14 (2007) 68-73
48. Shutter J., and Wright T.C. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol 24 (2005) 313-318
49. Kurman R.J., Kaminski P., and Norris H. The behaviour of endometrial hyperplasia. A long term study of "untreated" hyperplasia in 170 patients. Cancer 56 (1985) 403-412
50. Wentz W.B. Progestin therapy in endometrial hyperplasia. Obstet Gynecol 2 (1974) 362-367
51. Sherman A.I. Precursors of endometrial cancer. Isr J Med Sci 14 (1978) 370-378
52. Norris H.J., Connor M.P., and Kurman R.J. Preinvasive lesions of the endometrium. Clin Obstet Gynaecol 13 (1986) 725-738
53. Million Women Study Collaborators. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
54. Siiteri P.K. Adipose tissue as a source of hormones. Am J Clin Nutr 45 (1987) 277-282
55. Caspar R.F. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Studies 41 (1996) 16-21
56. Paterson M.E.L., Wade-Evans T., Sturdee D.W., et al. Endometrial disease after treatment with estrogens and progestogens in the climacteric. BMJ 280 (1980) 822-824
57. Whitehead M.I., McQueen J., Beard R.J., et al. The effects of cyclical estrogen therapy and sequential estrogen therapy on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 65 (1977) 91-101
58. Sturdee D.W., Wade-Evans T., Paterson M.E.L., et al. Relations between bleeding pattern, endometrial histology and estrogen treatment in postmenopausal women. BMJ 1 (1978) 1575-1577
59. Sturdee D.W., Ulrich L.G., Barlow D.H., et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynaecol 107 (2000) 1392-1400
60. Persson I., Adami H.O., Bergkvist L., et al. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens. Results of a prospective study. BMJ 298 (1989) 147-151
61. Beresford J.A.A., Weiss N.S., Voigt L.F., et al. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 349 (1997) 458-461
62. Ettinger B., Selby J., Citron J.T., et al. Cyclic HRT using quarterly progestin. Obstet Gynecol 83 (1994) 693-700
63. Bjarnason K., Cerin A., Lindgren R., et al. The Scandinavian Long Cycle Study Group. Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 32 (1999) 161-170
64. Pukkala E., Tulenheimo-Silfvast A., and Leminem A. Incidence of cancer among women using long versus monthly cyclical HRT, Finland 1994-1997. Cancer Causes Control 12 (2001) 111-115
65. Whitehead M.I., Townsend P.T., Pryse-Davies J., et al. Effects of estrogens and progestins on the biochemistry and morphology of a postmenopausal endometrium. N Engl J Med 305 (1981) 1599-1605
66. Wells M., Ulrich L.G., Sturdee D.W., et al. Effect on endometrium of long term treatment with continuous combined estrogen/progestogen replacement therapy: follow up study. BMJ 325 (2002) 239-242
67. Anderson G.L., Judd H.L., Kaunitz A.M., et al. Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomised trial. JAMA 290 (2003) 1739-1748
68. Archer D.F., Hendrix S., Gallagher J.C., et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 92 (2007) 911-918
69. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
70. Neven P., Lunde T., Benedetti-Panici P., et al. A multi-centre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing estradiol and norethisterone acetate. Br J Obstet Gynaecol 110 (2003) 157-167
71. Riphagen F.E. Intrauterine application of progestins in hormone replacement therapy. Climacteric 3 (2000) 199-211
72. Sturdee D.W., Archer D.F., Rakov V., et al. on behalf of the CHOICE study investigators. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved reading profile in postmenopausal women. Climacteric 11 (2008) 63-73
73. Grady D., Gebretsadik T., Kerliskowske K., et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 (1995) 304-313
74. Beral V., Banks E., Reeves G., et al. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4 (1999) 191-215
75. Paterson M.E., Allen J., and Jordan J.A. Effects of the climacteric and sequential mestronol and norethisterone on the cervix and genital tract. Br J Obstet Gynaecol 89 (1982) 657-664
76. International Agency for Research into Cancer. Monograph on the evaluation of carcogenic risk to humans. Combined Estrogen/Progestogen Contraceptives and Combined Estrogen/Progestogen Menopausal Therapy vol. 91 (2008), International Agency for Research on Cancer, Lyon
77. Tay S.K., Singer A., et al. The effects of oral contraceptive steroids, menopausal hormone replacement therapy on the cervical epithelium. In: Jordan J.A., Singer A., Jones H., and Shafi M. (Eds). The cervix. 2nd edn. (2006), Blackwell Publishing Limited, Oxford 128-144
78. Appleby P., Beral V., Berrington D., et al., International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative re-analysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370 (2007) 1609-1621
79. Brinton L.A., Reeves W.C., Brenes M.M., et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 19 (1990) 4-11
80. Hunt K., Vessey M.P., McPherson K., et al. Long term surveillance of mortality and cancer incidents in women receiving hormone replacement therapy. Br J Obstet Gynecol 94 (1987) 620-635
81. Leake R.E. Hormones and ovarian cancer. In: O'Brien P.M.S., and MacLean A.B. (Eds). Hormones and cancer (1999), RCOG Press, London 55-56
82. Whittemore A.S., Harris R., Itnyre J., and Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-controlled studies. Am J Epidemiol 136 (1992) 1184-1203
83. Franceschi S. Reproductive factors and cancer of the breast, ovary and endometrium. Eur J Cancer Clin Oncol 25 (1989) 1933-1943
84. Negri E., Franceschi S., Tzonou A., et al. Pulled analysis of three European case-controlled studies; re-productive factors and risks of ovarian cancer. Int J Cancer 49 (1991) 50-56
85. Franceschi S., La Vecchia C., Booth M., et al. Pulled analysis of three European case-controlled studies of ovarian cancer. Age at menarche and at menopause. Int J Cancer 49 (1991) 57-60
86. Vessey M.P., and Painter R. Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br J Cancer 71 (1995) 1340-1342
87. Hannaford P.C., Selvaraj S., Elliott A.M., et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners Oral Contraception Study. BMJ 335 (2007) 651-654
88. Rodriguez C., Calle E.E., Coates R.J., et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141 (1995) 828-835
89. Rodriguez C., Patel A.V., Calle E.E., et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (2001) 1460-1465
90. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women study. Lancet 369 (2007) 1703-1710
91. Riman T., Dickman P.W., Nilsson S., et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case controlled study. Am J Epidemiol 156 (2002) 363-373
92. Lacey J.V., Brinton L.A., Leitzmann M.F., et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst 98 (2006) 1397-1405
93. Rossing M.A., Cushing-Haugen K.L., Wicklund K.G., et al. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 2548-2556
94. Boyle P., and Langman M.J.S. ABC of colorectal cancer: clinical review. BMJ 321 (2000) 805-808
95. Willett W.C., Stampfer M.J., Colditz G.A., et al. Relation of meat, fat, and fibre intake to the risk of colon cancer in a prospective study among women. N Engl J Med 322 (1990) 1664-1672
96. Giovannucci E., Colditz G.A., Stampfer M.J., et al. Physical activity, obesity and risk of colorectal cancer in women (United States). Cancer Causes Control 7 (1996) 253-263
97. Al-Azzawi F., and Wahab M. Estrogen and colon cancer; current issues. Climacteric 5 (2002) 3-14
98. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., et al. The WHI Steering Committee. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350 (2004) 991-1004
99. Hulley S., Furberg C., Barrett-Connor E., et al., for the HERS research group. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow up (HERS II). JAMA 288 (2002) 58-66
100. Cirillo D.J., Wallace R.B., Rodabough R.J., et al. Effect of estrogen therapy on gall bladder disease. JAMA 293 (2005) 330-339
101. Gallus S., Negri E., Chatenoud L., et al. Post-menopausal hormonal therapy and gallbladder cancer risk. Int J Cancer 99 (2002) 762-763
102. Liu B., Beral V., Balkwill A., et al., for the Million Women Study Investigators. Gallbladder disease and use of transdermal versus oral replacement therapy in postmenopausal women: prospective cohort study. BMJ (2008) 337 a386
103. Smith M.A., Fine J.A., Barnhill R.L., et al. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 27 (1998) 751-757
104. Schabatch M.B., Wu X., Vassilopoulou-Sellin R., et al. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10 (2004) 113-123
105. Schwartz A.G., Wenzlaff A.S., Prysak G.M., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25 (2007) 5785-5792
106. Rodriguez C., Spencer Feigelson H., Deka A., et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 17 (2008) 655-660
107. Chen K.Y., Hsiao C.F., Chang G.C., et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 110 (2007) 1768-1775
108. Ganti A.K., Sahmoun A.E., Panwalkar A.W., et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24 (2006) 59-63
109. Lindblad M., Garcia Rodriguez L.A., Chandanos E., et al. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinoma. Br J Cancer 94 (2006) 136-141